pharma news today glp-1 obesity drug updates Major global in July 2026 feature massive market novo nordisk glp-1 receptor agonist

This provides ample nutritional support for tissue repair

Chronic UV exposure increases the risk of skin malignancies and accelerates photoaging (Pellacani et al

The FDA-approved prescribing information states that tesamorelin is not indicated for weight-loss management because it has a weight-neutral effect. In the Phase 3 studies, total body weight changed very little even though the tesamorelin groups demonstrated reductions in: Visceral adipose tissue Waist circumference Trunk fat At the same time, modest increases in lean body mass were reported

Thats where strength training on GLP-1 becomes essential-not optional